Identification of collateral sensitivity and evolutionary landscape of chemotherapy-induced drug resistance using cellular barcoding technology

One of the most significant challenges impeding cancer treatment effectiveness is drug resistance. Combining evolutionary understanding with drug resistance can pave the way for the identification of second-line drug options that can overcome drug resistance. Although capecitabine and irinotecan are...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 14; p. 1178489
Main Authors Danisik, Nurseda, Yilmaz, Kubra Celikbas, Acar, Ahmet
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 11.07.2023
Subjects
Online AccessGet full text

Cover

Loading…
Abstract One of the most significant challenges impeding cancer treatment effectiveness is drug resistance. Combining evolutionary understanding with drug resistance can pave the way for the identification of second-line drug options that can overcome drug resistance. Although capecitabine and irinotecan are commonly used therapeutic agents in the treatment of CRC patients, resistance to these agents is common. The underlying clonal dynamics of resistance to these agents using high-resolution barcode technology and identification of effective second-line drugs in this context remain unclear. Caco-2 and HT-29 cell lines were barcoded, and then capecitabine and irinotecan resistant derivatives of these cell lines were established. The frequencies of barcodes from resistant cell lines and harvested medium, longitudinally, were determined. Collateral drug sensitivity testing was carried out on resistant Caco-2 and HT-29 cell lines using single agents or drug combinations. The SyngeryFinder tool was used to analyse drug combination testing. In Caco-2 and HT-29 cell lines, barcode frequency measurements revealed clonal dynamics of capecitabine and irinotecan formed by both pre-existing and barcodes, indicating the presence of polyclonal drug resistance. The temporal dynamics of clonal evolution in Caco-2 and HT-29 cell lines were demonstrated by longitudinal analysis of pre-existing and barcodes from harvested medium. In Caco-2 and HT-29 cell lines, collateral drug sensitivity revealed a number of drugs that were effective alone and in combination. The use of barcoding technology reveals the clonal dynamics of chemotherapy-induced drug resistance not only from harvested cell populations, but also from longitudinal sampling throughout the course of clonal evolution. Second-line drugs that sensitize drug-resistant CRC cell lines are identified through collateral drug testing.
AbstractList Background: One of the most significant challenges impeding cancer treatment effectiveness is drug resistance. Combining evolutionary understanding with drug resistance can pave the way for the identification of second-line drug options that can overcome drug resistance. Although capecitabine and irinotecan are commonly used therapeutic agents in the treatment of CRC patients, resistance to these agents is common. The underlying clonal dynamics of resistance to these agents using high-resolution barcode technology and identification of effective second-line drugs in this context remain unclear. Methods and materials: Caco-2 and HT-29 cell lines were barcoded, and then capecitabine and irinotecan resistant derivatives of these cell lines were established. The frequencies of barcodes from resistant cell lines and harvested medium, longitudinally, were determined. Collateral drug sensitivity testing was carried out on resistant Caco-2 and HT-29 cell lines using single agents or drug combinations. The SyngeryFinder tool was used to analyse drug combination testing. Results: In Caco-2 and HT-29 cell lines, barcode frequency measurements revealed clonal dynamics of capecitabine and irinotecan formed by both pre-existing and de novo barcodes, indicating the presence of polyclonal drug resistance. The temporal dynamics of clonal evolution in Caco-2 and HT-29 cell lines were demonstrated by longitudinal analysis of pre-existing and de novo barcodes from harvested medium. In Caco-2 and HT-29 cell lines, collateral drug sensitivity revealed a number of drugs that were effective alone and in combination. Conclusion: The use of barcoding technology reveals the clonal dynamics of chemotherapy-induced drug resistance not only from harvested cell populations, but also from longitudinal sampling throughout the course of clonal evolution. Second-line drugs that sensitize drug-resistant CRC cell lines are identified through collateral drug testing.
Background: One of the most significant challenges impeding cancer treatment effectiveness is drug resistance. Combining evolutionary understanding with drug resistance can pave the way for the identification of second-line drug options that can overcome drug resistance. Although capecitabine and irinotecan are commonly used therapeutic agents in the treatment of CRC patients, resistance to these agents is common. The underlying clonal dynamics of resistance to these agents using high-resolution barcode technology and identification of effective second-line drugs in this context remain unclear.Methods and materials: Caco-2 and HT-29 cell lines were barcoded, and then capecitabine and irinotecan resistant derivatives of these cell lines were established. The frequencies of barcodes from resistant cell lines and harvested medium, longitudinally, were determined. Collateral drug sensitivity testing was carried out on resistant Caco-2 and HT-29 cell lines using single agents or drug combinations. The SyngeryFinder tool was used to analyse drug combination testing.Results: In Caco-2 and HT-29 cell lines, barcode frequency measurements revealed clonal dynamics of capecitabine and irinotecan formed by both pre-existing and de novo barcodes, indicating the presence of polyclonal drug resistance. The temporal dynamics of clonal evolution in Caco-2 and HT-29 cell lines were demonstrated by longitudinal analysis of pre-existing and de novo barcodes from harvested medium. In Caco-2 and HT-29 cell lines, collateral drug sensitivity revealed a number of drugs that were effective alone and in combination.Conclusion: The use of barcoding technology reveals the clonal dynamics of chemotherapy-induced drug resistance not only from harvested cell populations, but also from longitudinal sampling throughout the course of clonal evolution. Second-line drugs that sensitize drug-resistant CRC cell lines are identified through collateral drug testing.
One of the most significant challenges impeding cancer treatment effectiveness is drug resistance. Combining evolutionary understanding with drug resistance can pave the way for the identification of second-line drug options that can overcome drug resistance. Although capecitabine and irinotecan are commonly used therapeutic agents in the treatment of CRC patients, resistance to these agents is common. The underlying clonal dynamics of resistance to these agents using high-resolution barcode technology and identification of effective second-line drugs in this context remain unclear. Caco-2 and HT-29 cell lines were barcoded, and then capecitabine and irinotecan resistant derivatives of these cell lines were established. The frequencies of barcodes from resistant cell lines and harvested medium, longitudinally, were determined. Collateral drug sensitivity testing was carried out on resistant Caco-2 and HT-29 cell lines using single agents or drug combinations. The SyngeryFinder tool was used to analyse drug combination testing. In Caco-2 and HT-29 cell lines, barcode frequency measurements revealed clonal dynamics of capecitabine and irinotecan formed by both pre-existing and barcodes, indicating the presence of polyclonal drug resistance. The temporal dynamics of clonal evolution in Caco-2 and HT-29 cell lines were demonstrated by longitudinal analysis of pre-existing and barcodes from harvested medium. In Caco-2 and HT-29 cell lines, collateral drug sensitivity revealed a number of drugs that were effective alone and in combination. The use of barcoding technology reveals the clonal dynamics of chemotherapy-induced drug resistance not only from harvested cell populations, but also from longitudinal sampling throughout the course of clonal evolution. Second-line drugs that sensitize drug-resistant CRC cell lines are identified through collateral drug testing.
Author Acar, Ahmet
Yilmaz, Kubra Celikbas
Danisik, Nurseda
AuthorAffiliation Department of Biological Sciences , Middle East Technical University , Universiteler Mah , Ankara , Türkiye
AuthorAffiliation_xml – name: Department of Biological Sciences , Middle East Technical University , Universiteler Mah , Ankara , Türkiye
Author_xml – sequence: 1
  givenname: Nurseda
  surname: Danisik
  fullname: Danisik, Nurseda
  organization: Department of Biological Sciences, Middle East Technical University, Universiteler Mah, Ankara, Türkiye
– sequence: 2
  givenname: Kubra Celikbas
  surname: Yilmaz
  fullname: Yilmaz, Kubra Celikbas
  organization: Department of Biological Sciences, Middle East Technical University, Universiteler Mah, Ankara, Türkiye
– sequence: 3
  givenname: Ahmet
  surname: Acar
  fullname: Acar, Ahmet
  organization: Department of Biological Sciences, Middle East Technical University, Universiteler Mah, Ankara, Türkiye
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37497108$$D View this record in MEDLINE/PubMed
BookMark eNpVUs1u3CAYtKpUTZrmBXqoOPbiLRhsw6mqov6sFKmX9owwfLaJWNgCXmmfoq9cvLuNEi6gYWb4GM3b6soHD1X1nuANpVx8GvezipsGN3RDSM8ZF6-qG9J1tBacNFfPztfVXUqPuCwqBO3Ym-qa9kz0BPOb6u_WgM92tFplGzwKI9LBOZUhKocS-GSzPdh8RMobBIfglpWn4hG5giSt9nASzbALeS6q_bG23iwaDDJxmVCEZFNWXgNakvUT0uDc4lREg4o6mBXKoGcfXJiO76rXo3IJ7i77bfX729df9z_qh5_ft_dfHmrNOpHrljGqDONN22GOYeAAjIkWEy56TbDRjWaqEQwLyk2P2diKkQFrSiZDyymmt9X27GuCepT7aHflSzIoK09AiJNUMVvtQHZiJNCA6btBMaW5IpQPAxmIaIENPS9en89e-2XYgdEl0BLeC9OXN97OcgoHSTAtA3WkOHy8OMTwZ4GU5c6mNSflISxJNpyVmQu1LdTmTNUxpBRhfHqHYLk2Q56aIddmyEsziujD8wmfJP97QP8B5r-7jg
CitedBy_id crossref_primary_10_3389_fcell_2024_1369597
crossref_primary_10_1371_journal_pone_0291942
crossref_primary_10_1038_s41598_023_50443_3
Cites_doi 10.1158/0008-5472.CAN-08-3658
10.1038/nm.4040
10.3390/cancers13194923
10.1038/s41576-019-0114-6
10.1111/cas.12366
10.18632/oncotarget.16723
10.3322/caac.21660
10.1126/scitranslmed.3006609
10.1126/science.aao2774
10.1038/nm.3967
10.1016/j.cell.2016.01.045
10.1038/s41588-020-0675-5
10.15586/jkcvhl.2016.46
10.3389/fimmu.2021.656364
10.1186/gb-2014-15-5-r75
10.1016/j.bbcan.2017.01.003
10.1016/j.clcc.2014.11.002
10.1038/nrc3599
10.1016/j.tim.2015.02.009
10.1038/s41598-017-00791-8
10.1038/s41467-020-15596-z
10.1038/nature11252
10.1038/nrg3922
10.3389/fonc.2014.00086
10.1038/nrc2013
10.1016/j.molonc.2014.06.005
10.1038/nm.3841
10.1016/j.ccell.2019.05.001
10.1158/2159-8290.CD-20-1311
10.1073/PNAS.1806109115
10.1016/j.cell.2018.04.012
10.3390/cancers6031769
10.1126/science.abm5874
10.1038/nmeth.4197
10.1038/s41586-019-1730-1
10.1371/journal.pcbi.1004493
10.1093/bioinformatics/btu170
10.1016/j.dnarep.2021.103177
10.3390/jpm10040180
10.1371/journal.pone.0232565
ContentType Journal Article
Copyright Copyright © 2023 Danisik, Yilmaz and Acar.
Copyright © 2023 Danisik, Yilmaz and Acar. 2023 Danisik, Yilmaz and Acar
Copyright_xml – notice: Copyright © 2023 Danisik, Yilmaz and Acar.
– notice: Copyright © 2023 Danisik, Yilmaz and Acar. 2023 Danisik, Yilmaz and Acar
DBID NPM
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.3389/fphar.2023.1178489
DatabaseName PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList
CrossRef

PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Danisik et al
EISSN 1663-9812
EndPage 1178489
ExternalDocumentID oai_doaj_org_article_69f1e2ed76ba4ac8a138bb1b195e4b78
10_3389_fphar_2023_1178489
37497108
Genre Journal Article
GrantInformation_xml – fundername: ;
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
DIK
EMOBN
GROUPED_DOAJ
GX1
HYE
IAO
IEA
IHR
IHW
IPNFZ
KQ8
M48
M~E
NPM
O5R
O5S
OK1
P2P
PGMZT
RIG
RNS
RPM
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c469t-5443ad48256080eb8ee449501897c10dc2c4a2940938d704f59f4e42663b58303
IEDL.DBID RPM
ISSN 1663-9812
IngestDate Tue Oct 22 15:11:45 EDT 2024
Tue Sep 17 21:30:37 EDT 2024
Thu Oct 24 22:52:32 EDT 2024
Thu Sep 26 16:05:19 EDT 2024
Sat Sep 28 08:09:26 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords cancer
drug resistance
colorectal
collateral sensitivity
cellular barcoding
Language English
License Copyright © 2023 Danisik, Yilmaz and Acar.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c469t-5443ad48256080eb8ee449501897c10dc2c4a2940938d704f59f4e42663b58303
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Joao M. Fernandes Neto, The Netherlands Cancer Institute (NKI), Netherlands
Edited by: Beatriz Carvalho, The Netherlands Cancer Institute (NKI), Netherlands
Tejveer Singh, University of Delhi, India
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366361/
PMID 37497108
PQID 2843036365
PQPubID 23479
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_69f1e2ed76ba4ac8a138bb1b195e4b78
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10366361
proquest_miscellaneous_2843036365
crossref_primary_10_3389_fphar_2023_1178489
pubmed_primary_37497108
PublicationCentury 2000
PublicationDate 2023-07-11
PublicationDateYYYYMMDD 2023-07-11
PublicationDate_xml – month: 07
  year: 2023
  text: 2023-07-11
  day: 11
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in pharmacology
PublicationTitleAlternate Front Pharmacol
PublicationYear 2023
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Davis (B7) 2017; 1867
Dhawan (B8) 2017; 7
Patro (B39) 2017; 14
Vlachogiannis (B35) 2018; 359
Yalcin (B37) 2020; 10
Fang (B9) 2019; 35
Bhang (B3) 2015; 21
(B26) 2020
Sankaran (B30) 2022; 378
Housman (B16) 2014; 6
Turajlic (B33) 2019; 20
Kirkman (B21) 2018; 115
Hata (B13) 2016; 22
Mokhtari (B24) 2017; 8
Zhao (B38) 2016; 165
Guinney (B11) 2015; 21
Imamovic (B18) 2013; 5
Ray (B40) 2021; 106
Gatenby (B10) 2009; 69
Merlo (B23) 2006; 6
Caravagna (B5) 2020; 52
Acar (B1) 2020; 11
Wang (B36) 2018; 173
Burrell (B4) 2014; 8
Vasan (B34) 2019; 575
Porter (B29) 2014; 15
Holohan (B15) 2013; 13
Khalaf (B20) 2021; 12
Gustavsson (B12) 2015; 14
Sung (B32) 2021; 71
Chowdhury (B6) 2021; 13
Bolger (B41) 2014; 30
Hirsch (B14) 2016; 3
Alix-Panabières (B2) 2021; 11
Jekimovs (B19) 2014; 4
Muzny (B25) 2012; 487
Hughes (B17) 2015; 16
Li (B22) 2015; 19
Pál (B28) 2015; 23
Suarez-Arnedo (B31) 2020; 15
Hosoya (B42) 2014; 105
Nichol (B27) 2015; 11
References_xml – volume: 69
  start-page: 4894
  year: 2009
  ident: B10
  article-title: Adaptive therapy
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-08-3658
  contributor:
    fullname: Gatenby
– volume: 22
  start-page: 262
  year: 2016
  ident: B13
  article-title: Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
  publication-title: Nat. Med.
  doi: 10.1038/nm.4040
  contributor:
    fullname: Hata
– volume: 13
  start-page: 4923
  year: 2021
  ident: B6
  article-title: Implications of intratumor heterogeneity on consensus molecular subtype (Cms) in colorectal cancer
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers13194923
  contributor:
    fullname: Chowdhury
– volume: 20
  start-page: 404
  year: 2019
  ident: B33
  article-title: Resolving genetic heterogeneity in cancer
  publication-title: Nat. Rev. Genet.
  doi: 10.1038/s41576-019-0114-6
  contributor:
    fullname: Turajlic
– volume: 105
  start-page: 370
  year: 2014
  ident: B42
  article-title: Targeting DNA damage response in cancer therapy
  publication-title: Cancer Sci.
  doi: 10.1111/cas.12366
  contributor:
    fullname: Hosoya
– volume: 8
  start-page: 38022
  year: 2017
  ident: B24
  article-title: Combination therapy in combating cancer
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.16723
  contributor:
    fullname: Mokhtari
– volume: 71
  start-page: 209
  year: 2021
  ident: B32
  article-title: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21660
  contributor:
    fullname: Sung
– volume: 5
  start-page: 204ra132
  year: 2013
  ident: B18
  article-title: Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.3006609
  contributor:
    fullname: Imamovic
– volume: 359
  start-page: 920
  year: 2018
  ident: B35
  article-title: Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
  publication-title: Science
  doi: 10.1126/science.aao2774
  contributor:
    fullname: Vlachogiannis
– volume: 21
  start-page: 1350
  year: 2015
  ident: B11
  article-title: The consensus molecular subtypes of colorectal cancer
  publication-title: Nat. Med.
  doi: 10.1038/nm.3967
  contributor:
    fullname: Guinney
– volume: 165
  start-page: 234
  year: 2016
  ident: B38
  article-title: Exploiting temporal collateral sensitivity in tumor clonal evolution
  publication-title: Cell.
  doi: 10.1016/j.cell.2016.01.045
  contributor:
    fullname: Zhao
– volume: 52
  start-page: 898
  year: 2020
  ident: B5
  article-title: Subclonal reconstruction of tumors by using machine learning and population genetics
  publication-title: Nat. Genet.
  doi: 10.1038/s41588-020-0675-5
  contributor:
    fullname: Caravagna
– volume: 3
  start-page: 23
  year: 2016
  ident: B14
  article-title: Sequential therapy in metastatic renal cell carcinoma
  publication-title: J. Kidney Cancer VHL
  doi: 10.15586/jkcvhl.2016.46
  contributor:
    fullname: Hirsch
– volume: 12
  start-page: 656364
  year: 2021
  ident: B20
  article-title: Aspects of the tumor microenvironment involved in immune resistance and drug resistance
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.656364
  contributor:
    fullname: Khalaf
– volume: 15
  start-page: R75
  year: 2014
  ident: B29
  article-title: Lentiviral and targeted cellular barcoding reveals ongoing clonal dynamics of cell lines in vitro and in vivo
  publication-title: Genome Biol.
  doi: 10.1186/gb-2014-15-5-r75
  contributor:
    fullname: Porter
– volume: 1867
  start-page: 151
  year: 2017
  ident: B7
  article-title: Tumor evolution: Linear, branching, neutral or punctuated?
  publication-title: Biochim. Biophys. Acta Rev. Cancer
  doi: 10.1016/j.bbcan.2017.01.003
  contributor:
    fullname: Davis
– volume-title: Colorectal cancer NICE guideline
  year: 2020
  ident: B26
– volume: 14
  start-page: 1
  year: 2015
  ident: B12
  article-title: A review of the evolution of systemic chemotherapy in the management of colorectal cancer
  publication-title: Clin. Colorectal Cancer
  doi: 10.1016/j.clcc.2014.11.002
  contributor:
    fullname: Gustavsson
– volume: 13
  start-page: 714
  year: 2013
  ident: B15
  article-title: Cancer drug resistance: An evolving paradigm
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc3599
  contributor:
    fullname: Holohan
– volume: 23
  start-page: 401
  year: 2015
  ident: B28
  article-title: Collateral sensitivity of antibiotic-resistant microbes
  publication-title: Trends Microbiol.
  doi: 10.1016/j.tim.2015.02.009
  contributor:
    fullname: Pál
– volume: 7
  start-page: 1232
  year: 2017
  ident: B8
  article-title: Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-017-00791-8
  contributor:
    fullname: Dhawan
– volume: 11
  start-page: 1923
  year: 2020
  ident: B1
  article-title: Exploiting evolutionary steering to induce collateral drug sensitivity in cancer
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-15596-z
  contributor:
    fullname: Acar
– volume: 487
  start-page: 330
  year: 2012
  ident: B25
  article-title: Comprehensive molecular characterization of human colon and rectal cancer
  publication-title: Nature
  doi: 10.1038/nature11252
  contributor:
    fullname: Muzny
– volume: 16
  start-page: 459
  year: 2015
  ident: B17
  article-title: Evolutionary consequences of drug resistance: Shared principles across diverse targets and organisms
  publication-title: Nat. Rev. Genet.
  doi: 10.1038/nrg3922
  contributor:
    fullname: Hughes
– volume: 4
  start-page: 86
  year: 2014
  ident: B19
  article-title: Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: The good, the bad, and the promising
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2014.00086
  contributor:
    fullname: Jekimovs
– volume: 6
  start-page: 924
  year: 2006
  ident: B23
  article-title: Cancer as an evolutionary and ecological process
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc2013
  contributor:
    fullname: Merlo
– volume: 8
  start-page: 1095
  year: 2014
  ident: B4
  article-title: Tumour heterogeneity and the evolution of polyclonal drug resistance
  publication-title: Mol. Oncol.
  doi: 10.1016/j.molonc.2014.06.005
  contributor:
    fullname: Burrell
– volume: 21
  start-page: 440
  year: 2015
  ident: B3
  article-title: Studying clonal dynamics in response to cancer therapy using high-complexity barcoding
  publication-title: Nat. Med.
  doi: 10.1038/nm.3841
  contributor:
    fullname: Bhang
– volume: 35
  start-page: 851
  year: 2019
  ident: B9
  article-title: Sequential therapy with PARP and WEE1 inhibitors minimizes toxicity while maintaining efficacy
  publication-title: Cancer Cell.
  doi: 10.1016/j.ccell.2019.05.001
  contributor:
    fullname: Fang
– volume: 11
  start-page: 858
  year: 2021
  ident: B2
  article-title: Liquid biopsy: From discovery to clinical application
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-20-1311
  contributor:
    fullname: Alix-Panabières
– volume: 115
  start-page: E6863
  year: 2018
  ident: B21
  article-title: Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance
  publication-title: Proc. Natl. Acad. Sci.
  doi: 10.1073/PNAS.1806109115
  contributor:
    fullname: Kirkman
– volume: 19
  start-page: 2812
  year: 2015
  ident: B22
  article-title: The irradiated-fibroblasts elicit immune response against tumor in a murine colon cancer model
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
  contributor:
    fullname: Li
– volume: 173
  start-page: 1413
  year: 2018
  ident: B36
  article-title: An acquired vulnerability of drug-resistant melanoma with therapeutic potential
  publication-title: Cell.
  doi: 10.1016/j.cell.2018.04.012
  contributor:
    fullname: Wang
– volume: 6
  start-page: 1769
  year: 2014
  ident: B16
  article-title: Drug resistance in cancer: An overview
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers6031769
  contributor:
    fullname: Housman
– volume: 378
  start-page: eabm5874
  year: 2022
  ident: B30
  article-title: Cellular barcoding to decipher clonal dynamics in disease
  publication-title: Science
  doi: 10.1126/science.abm5874
  contributor:
    fullname: Sankaran
– volume: 14
  start-page: 417
  year: 2017
  ident: B39
  article-title: Salmon provides fast and bias-aware quantification of transcript expression
  publication-title: Nat. Methods
  doi: 10.1038/nmeth.4197
  contributor:
    fullname: Patro
– volume: 575
  start-page: 299
  year: 2019
  ident: B34
  article-title: A view on drug resistance in cancer
  publication-title: Nature
  doi: 10.1038/s41586-019-1730-1
  contributor:
    fullname: Vasan
– volume: 11
  start-page: e1004493
  year: 2015
  ident: B27
  article-title: Steering evolution with sequential therapy to prevent the emergence of bacterial antibiotic resistance
  publication-title: PLoS Comput. Biol.
  doi: 10.1371/journal.pcbi.1004493
  contributor:
    fullname: Nichol
– volume: 30
  start-page: 2114
  year: 2014
  ident: B41
  article-title: Trimmomatic: a flexible trimmer for Illumina sequence data
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btu170
  contributor:
    fullname: Bolger
– volume: 106
  start-page: 103177
  year: 2021
  ident: B40
  article-title: Understanding the DNA double-strand break repair and its therapeutic implications
  publication-title: DNA Repair
  doi: 10.1016/j.dnarep.2021.103177
  contributor:
    fullname: Ray
– volume: 10
  start-page: 180
  year: 2020
  ident: B37
  article-title: Systems biology and experimental model systems of cancer
  publication-title: J. Pers. Med.
  doi: 10.3390/jpm10040180
  contributor:
    fullname: Yalcin
– volume: 15
  start-page: e0232565
  year: 2020
  ident: B31
  article-title: An image J plugin for the high throughput image analysis of in vitro scratch wound healing assays
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0232565
  contributor:
    fullname: Suarez-Arnedo
SSID ssj0000399364
Score 2.383703
Snippet One of the most significant challenges impeding cancer treatment effectiveness is drug resistance. Combining evolutionary understanding with drug resistance...
Background: One of the most significant challenges impeding cancer treatment effectiveness is drug resistance. Combining evolutionary understanding with drug...
Background: One of the most significant challenges impeding cancer treatment effectiveness is drug resistance. Combining evolutionary understanding with drug...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 1178489
SubjectTerms cancer
cellular barcoding
collateral sensitivity
colorectal
drug resistance
Pharmacology
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQT70gaPlYKGiQUC80apzYsX0ERFUhgXpopd4sO7a7SJCt9gNpfwV_mRk73e4iJC5cd5Os5TfeN8-ZeWbsrWqpAZPKBknpCMNj5ZRKFXKh66Xj2gTa7_jytTu_Ep-v5fXWUV9UE1bsgcvEnXYm8djEoDrvhOu14632nntuZBRelTbf2myJqfwfTLzbidIlgyrMnKbbqSP_z6al95Ra0LnuW0yUDfv_lmX-WSy5xT5nj9jDMW2E92W4j9mDOByw44viO70-gcv7NqrFCRzDxb0j9fqQ_SrtuGncn4NZgow_dR9_hwXVsJdDJMANAeLPMRzdfA25FZiKpPJN0_hj7NhaVyjmMSwChPnqBlC0UyKKEQRUSX8D9EKAKlzB40qaEUHCcrOL_4RdnX26_HhejScxVD3K52VFJnkuCE35ka6j1zEKVFY1Qql6Xoe-6YVrDGrFVgdViyRNEpHIv_VSI0s-ZXvDbIjPGSiTtOmavnUJkxkhnZMiSCk7h1d3SUzYuztU7G0x3LAoVAhDmzG0hKEdMZywDwTc5koyy84fYAjZMYTsv0Jowt7cwW5xcdEEuSHOVguL3E0U33Zywp6VMNj8VKuEwfQM79Y7AbIzlt1vhm_TbODN8Zn4UP7if4z-JdunGaH9Zs6P2N5yvoqvMFFa-td5TfwGiowVrg
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1db9MwFL0aQ0J7QXyT8SEjob2wQJ3Ysf2AECCmCQm0h1XaW-TEdos0ki1tEfkV_GXuddKOou21TZ0m9zjnHOfea4DXKqcCTEobJKcjDPepVSqkyIW2lpZr42i949v34ngqvp7Jsx1Yb3c03sDFtdaO9pOadudvf1_2H3DCvyfHiXz7LlzMLbX2zHJ6BamFNrfgdibQqVMq3yj345OZ2Dh2lOJItKlBchvqaG4YZg_u5EoYJGG9RVuxu_91kvT_zMp_qOroHtwdNSb7OIDiPuz45gEcnAxNqvtDdnpVc7U4ZAfs5Kp9df8Q_gy1u2FczGNtYBEsVKp8zhaU8D7sOMFs45j_NWLXdj2LdcOUURV_NPc_x_KuPkXnjxhyzHWrGUOHT6oV4cYo7X7G6O0BpcOyCqddS2zKlpsl_0cwPfpy-vk4HbdtSGv02suUOupZJzSJKT3xlfZeoA2bYNxVzSeuzmphM4PGMtdOTUSQJghPSiGvpEZKfQy7Tdv4p8CUCdoUWZ3bgMpHSGulcFLKwuLRRRAJvFlHpbwYunOU6GoonGUMZ0nhLMdwJvCJArc5kjprxw_ablaOE7UsTOA-804VlRW21pbnuqp4xY30olI6gVfrsJc4E-kG2ca3q0WJRE96IC9kAk8GGGxOtYZRAnoLIFv_Zfub5sc8dvvmOCYOyvdvHPQZ7NFl0ooz589hd9mt_AuUSsvqZcT_X0A9EiY
  priority: 102
  providerName: Scholars Portal
Title Identification of collateral sensitivity and evolutionary landscape of chemotherapy-induced drug resistance using cellular barcoding technology
URI https://www.ncbi.nlm.nih.gov/pubmed/37497108
https://search.proquest.com/docview/2843036365
https://pubmed.ncbi.nlm.nih.gov/PMC10366361
https://doaj.org/article/69f1e2ed76ba4ac8a138bb1b195e4b78
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswECWSnHoputddAhYocmkUm-Ii8tgGDYICLnxIgNwIUiLtALFkeCngr-gvd4aSHLvoqRcdJBES9IZ684YzQ0I-FxwLMDFtEJWOMCxkrihiBlzoSumYNhXGO8Y_1fWt-HEn746I6mthUtJ-6e8v6of5RX0_S7mVi3k57PPEhpPxJYPfruKKDY_JMVjonkZP_1_kXCXaChlQYGYYFzOHvT9zjmuUWuCe7nsslJr1_8vD_DtRco95rp6Rp53LSL-2r_acHIX6BTmbtD2nt-f05rGEanVOz-jksRv19iX53Zbixi42R5tIE_ZYefxAV5i_3m4gQV1d0fCrM0W33NJUBowJUmnQLMy7aq1tBkIeTKKi1XIzpSDY0QkF66GYRT-luBiA2a3UwyxqkBzpehfBf0Vur77fXF5n3S4MWQnSeZ1hgzxXCY2-kR4Fr0MQoKpGAGNRslFV5qVwuQGdyHVVjESUJoqAxM-91MCQr8lJ3dThLaGFidqovOQugiMjpHNSVFJK5eBuFcWAfOlRsYu22YYFkYIY2oShRQxth-GAfEPgdndio-x0ollObWcuVpnIQh6qQnknXKkd49p75pmRQfhCD8inHnYLEws_kKtDs1lZ4G2kd67kgLxpzWD3KF4IA64ZjNYHBnLwLodXwJZT8-7edt_9_9D35Al-B4wwM_aBnKyXm_ARXKO1P00hBTiOhT5Ns-IPw5wVuA
link.rule.ids 230,315,730,783,787,867,888,2109,24330,27936,27937,53804,53806
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LjpswFLWm00W76fuRPl2pmk2HBINtzLIddZS2k1EWGXV2yAaTRJ1AREil9Cf6y73XQCYZddNuAQswx9xz7XOPCXkfhViAibJBzHR4zKynoyj3IBbqVGim4gznO0bncnjBv16KywMiu1oYJ9pPzbxfXC36xXzmtJXLRTrodGKD8eiEwW9XhpINbpHbMGB9vpOluz8wRl3JmxoZyMHiQb6caXT_DEJcpVQcd3XfiUPOrv9vHPOmVHIn9pzeJ9-7p24kJz_669r00183DB3__bUekHstHaUfm_MPyYEtHpGjceNnvTmmk-vyrNUxPaLja6frzWPyuynzzdt5P1rm1OEKq5qv6Aq18c3mFFQXGbU_W5jrakNdiTGKr1yjmV20lWAbb15kALeMZtV6Siu7QoILyKSo0J9SXGhA5Sw1MEJLDLy03q4OPCEXp58nJ0Ov3eHBSyEtrz0039MZV8i7lG-NspZDxuYDRKKU-VkapFwHMeSgocoin-cizrlFUhEaoSD6PiWHRVnY54RGca5iGaShzoEkcaG14JkQQmq4Wua8Rz503ztZNkYeCSRAiI7EoSNBdCQtOnrkE0JieyWacLsDZTVN2m-WyDhnNrBZJI3mOlWahcoYZlgsLDeR6pF3HaASGLTYQbqw5XqVACdA6hBK0SPPGoBtbxVGPAbaB63VHvT2nmX_DADKGYN3AHrx_03fkjvDyegsOfty_u0luYt9gjPZjL0ih3W1tq-BgtXmjRtvfwCV7jYK
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswECXaFCh66d7UXVmgyKWRZVokRR3btEa6JPAhAQL0IHC1jcayIdsF3J_oL3dGi2MHPeUqkdD2qHlDvnkk5H2aYAEmygYx0-EZ85FO0xBBLNRWaKYyh_MdJ6fy-Jx_uxAXjapy0cgqC2sm3eJy2i0m40pbOZ_auNWJxcOTIwa_XZlIFs9diG-TOzBoe3IrU6_-whh5Ja_rZCAPy-IwH2t0AO0nuFKpOO7svhWLKsv-__HM63LJrfgzeEB-tndey05-dVdL07V_rpk63uzRHpL7DS2lH-s2j8gtXzwmB8Pa13p9SM-uyrQWh_SADq8cr9dPyN-63Dc08390FmiFL6xuvqQL1MjXm1RQXTjqfzdw1-WaVqXGKMKqOo39tKkIW0eTwgHsHHXlakRLv0CiCwilqNQfUVxwQAUtNTBSZxiA6XKzSvCUnA--nB0dR81OD5GF9HwZoQmfdlwh_1I9b5T3HDK3HkAltaznbN9y3c8gF02US3s8iCxwj-QiMUJBFH5G9opZ4Z8TmmZBZbJvEx2ALHGhteBOCCE1tJaBd8iH9pvn89rQI4dECBGSVwjJESF5g5AO-YSw2LREM-7qwKwc5c13y2UWmO97l0qjubZKs0QZwwzLhOcmVR3yrgVVDoMXX5Au_Gy1yIEbIIVIpOiQ_Rpkm0slKc-A_kFvtQO_nXvZPQOgqgzCWxC9uHnXt-Tu8PMg__H19PtLcg9fCU5oM_aK7C3LlX8NTGxp3lRD7h8RsjiK
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Identification+of+collateral+sensitivity+and+evolutionary+landscape+of+chemotherapy-induced+drug+resistance+using+cellular+barcoding+technology&rft.jtitle=Frontiers+in+pharmacology&rft.au=Danisik%2C+Nurseda&rft.au=Yilmaz%2C+Kubra+Celikbas&rft.au=Acar%2C+Ahmet&rft.date=2023-07-11&rft.issn=1663-9812&rft.eissn=1663-9812&rft.volume=14&rft.spage=1178489&rft_id=info:doi/10.3389%2Ffphar.2023.1178489&rft_id=info%3Apmid%2F37497108&rft.externalDocID=37497108
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon